KR20240137110A - 오미크론 코로나바이러스 백신 구조체 및 이를 제조하고 사용하는 방법 - Google Patents

오미크론 코로나바이러스 백신 구조체 및 이를 제조하고 사용하는 방법 Download PDF

Info

Publication number
KR20240137110A
KR20240137110A KR1020247029519A KR20247029519A KR20240137110A KR 20240137110 A KR20240137110 A KR 20240137110A KR 1020247029519 A KR1020247029519 A KR 1020247029519A KR 20247029519 A KR20247029519 A KR 20247029519A KR 20240137110 A KR20240137110 A KR 20240137110A
Authority
KR
South Korea
Prior art keywords
cov
sars
chad
mice
adenovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247029519A
Other languages
English (en)
Korean (ko)
Inventor
마이클 다이아몬드
이고르 드미트리브
아메드 하산
데이비드 쿠리엘
Original Assignee
워싱턴 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 워싱턴 유니버시티 filed Critical 워싱턴 유니버시티
Publication of KR20240137110A publication Critical patent/KR20240137110A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247029519A 2022-02-02 2023-02-02 오미크론 코로나바이러스 백신 구조체 및 이를 제조하고 사용하는 방법 Pending KR20240137110A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263305979P 2022-02-02 2022-02-02
US63/305,979 2022-02-02
US202263375803P 2022-09-15 2022-09-15
US63/375,803 2022-09-15
US202263384075P 2022-11-16 2022-11-16
US63/384,075 2022-11-16
US202263434815P 2022-12-22 2022-12-22
US63/434,815 2022-12-22
PCT/US2023/061878 WO2023150638A2 (en) 2022-02-02 2023-02-02 Omicron coronavirus vaccine constructs and methods of making and using same

Publications (1)

Publication Number Publication Date
KR20240137110A true KR20240137110A (ko) 2024-09-19

Family

ID=87552962

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247029519A Pending KR20240137110A (ko) 2022-02-02 2023-02-02 오미크론 코로나바이러스 백신 구조체 및 이를 제조하고 사용하는 방법

Country Status (7)

Country Link
EP (1) EP4473122A4 (https=)
JP (1) JP2025508676A (https=)
KR (1) KR20240137110A (https=)
CN (1) CN120282795A (https=)
AU (1) AU2023216258A1 (https=)
CA (1) CA3243465A1 (https=)
WO (1) WO2023150638A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250228929A1 (en) * 2022-04-03 2025-07-17 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant
CN116987184B (zh) * 2023-09-26 2024-01-12 北京百普赛斯生物科技股份有限公司 新型冠状病毒bq.1.1突变株特异性抗体及其应用
WO2025202543A1 (en) * 2024-03-28 2025-10-02 Rokote Laboratories Finland Oy A vaccine composition comprising an adenoviral vector and an adenoviral vector delivery enhancing agent
WO2025250851A1 (en) * 2024-05-29 2025-12-04 Washington University Trivalent pan-sarbecovirus mucosal vaccine constructs and methods of making and using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2716928C (en) * 2008-03-04 2018-04-10 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
CA3167833A1 (en) * 2020-02-14 2021-08-19 Bertrand Victor Gilbert GEORGES Coronavirus immunogenic compositions and uses thereof
MX2022013934A (es) * 2020-05-07 2023-02-22 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle recombinante que expresa la proteina de espicula de sars-cov-2 y usos del mismo.
WO2021247567A1 (en) * 2020-06-01 2021-12-09 Washington University Coronavirus vaccine constructs and methods of making and using same

Also Published As

Publication number Publication date
EP4473122A4 (en) 2026-03-04
AU2023216258A1 (en) 2024-08-01
WO2023150638A2 (en) 2023-08-10
EP4473122A2 (en) 2024-12-11
JP2025508676A (ja) 2025-04-10
WO2023150638A3 (en) 2023-09-14
CN120282795A (zh) 2025-07-08
CA3243465A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
US11382968B2 (en) Coronavirus immunogenic compositions and uses thereof
US20230075527A1 (en) Compositions and Methods for Preventing and Treating Coronavirus Infection - Sars-Cov-2 Vaccines
KR20240137110A (ko) 오미크론 코로나바이러스 백신 구조체 및 이를 제조하고 사용하는 방법
US20220054629A1 (en) Nucleic acid based vaccine against middle east respiratory syndrome-coronavirus
US20210260181A1 (en) Coronavirus immunogenic compositions and uses thereof
EP4106809A1 (en) Vaccine compositions for preventing coronavirus disease
CA3101131A1 (en) Compositions and methods for preventing and treating coronavirus infection - sars­cov-2 vaccines
KR20170068410A (ko) 엔테로바이러스 감염증에 대항하는 아데노바이러스 벡터-기반 백신
CN114213548B (zh) 同时诱导抗多种病毒的免疫应答的方法
JP2023524990A (ja) ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質を発現する組換えニューカッスル病ウイルス及びその使用
JP2024530047A (ja) ワクチン抗原
US20230227848A1 (en) Coronavirus vaccine constructs and methods of making and using same
US20250049912A1 (en) Multicistronic Vaccine and Methods for Producing and Using the Same
US20240293532A1 (en) Replication-competent adenovirus type 4 sars-cov-2 vaccines and their use
CN120019142A (zh) 水疱性口炎病毒马尔堡病毒疫苗
Cicin-Sain et al. MCMV based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination
Chu et al. Zi-Wei Ye1†, Shuofeng Yuan1†, Kwok-Man Poon1, Lei Wen1, Dong Yang1, Zehua Sun1, Cun Li1, Meng Hu1, Huiping Shuai1, Jie Zhou1, 2, Mei-Yun Zhang1, Bo-Jian Zheng1, Hin Chu1, 2*‡ and Kwok-Yung Yuen1, 2, 3, 4
WO2026055587A1 (en) Vesicular stomatitis virus marburg virus vaccine
WO2021173965A1 (en) Identification of variable influenza residues and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000